Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Raises Questions About Trial Exclusion in DLBCL

Key clinical point: High-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who meet trial eligibility but require urgent treatment are being widely excluded from clinical trials.

Major finding: The clinical trial accrual rate was 18%. Of 207 patients who were not enrolled, 43 were excluded because of a perceived need for urgent treatment due to symptoms or rapid progression.

Study details: A retrospective analysis of 251 patients with newly diagnosed DLBCL.

Disclosures: No funding sources were reported. The authors reported financial relationships with Genentech, Bayer, Ascerta, Curis, and Kite Gilead.

Citation:

Loh KP et al. Leuk Lymphoma. 2019 Jul 8. doi: 10.1080/10428194.2019.1639172